Charles River Announces Strategic Partnership with Bit Bio,
Dec. 10, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive Discovery and Safety Services partnership with Bit Bio, a company that offers consistent and efficient reprogramming of human cells for use in research, drug discovery, and cell therapies.
By applying an engineering approach to synthetic and stem cell biology, Bit Bio has developed proprietary technologies for the efficient, consistent, and scalable reprogramming of induced pluripotent stem cells.
Cellular reprogramming is the process by which human stem cells, given a precise set of genetic instructions, differentiate into a desired cell type. Current cellular reprogramming approaches are inefficient, with low cell yields, creating a gap for applications requiring high quality, consistent, and pure human cells.
To overcome this hurdle, Bit Bio has developed a gene engineering approach, opti-ox (optimised inducible